Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA (2020 - 2022)

Atea Pharmaceuticals has reported EBITDA over the past 3 years, most recently at -$34.3 million for Q4 2022.

  • Quarterly results put EBITDA at -$34.3 million for Q4 2022, down 129.25% from a year ago — trailing twelve months through Dec 2022 was -$116.6 million (down 190.89% YoY), and the annual figure for FY2025 was -$158.4 million, up 5.91%.
  • EBITDA for Q4 2022 was -$34.3 million at Atea Pharmaceuticals, down from -$8.9 million in the prior quarter.
  • Over the last five years, EBITDA for AVIR hit a ceiling of $117.1 million in Q4 2021 and a floor of -$42.1 million in Q1 2022.
  • Median EBITDA over the past 3 years was -$9.5 million (2020), compared with a mean of $54750.0.
  • Biggest five-year swings in EBITDA: surged 857.85% in 2021 and later plummeted 460.71% in 2022.
  • Atea Pharmaceuticals' EBITDA stood at $20.6 million in 2020, then surged by 467.31% to $117.1 million in 2021, then tumbled by 129.25% to -$34.3 million in 2022.
  • The last three reported values for EBITDA were -$34.3 million (Q4 2022), -$8.9 million (Q3 2022), and -$31.3 million (Q2 2022) per Business Quant data.